Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric Xyrem trial in narcolepsy with cataplexy
NL-OMON45197Phase 2Active, not recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sodium oxybate in narcolepsy and narcolepsy type 1 (NT1) (4 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Change in weekly number of cataplexy attacks. Started Aug 2015; status: active, not recruiting.
02
Drugs
sodium oxybate
03
Conditions
narcolepsynarcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NL-OMON45197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45197.